BRAIN Biotech FY26 9M net loss widens to EUR 9.93 million; revenue falls 10.5% to EUR 34.64 million

• BRAIN Biotech posted 9M FY2025/26 revenue of EUR 34.64 million, down 10.5% year over year.
• Net loss attributable to shareholders widened to EUR 9.93 million; diluted EPS was EUR -0.45.
• EBITDA loss widened to EUR 2 million; adjusted EBITDA loss was EUR 712,000 under IFRS.
• Cash and cash equivalents fell to EUR 940,000 at June 30, 2026; IFRS equity turned negative at EUR -7.12 million.
• New EUR 9 million revolving credit line agreed with MP Beteiligungs-GmbH through Dec. 31, 2028; Dr. Sven K. Weber named incoming CEO from Oct. 1, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BRAIN Biotech AG published the original content used to generate this news brief on August 27, 2026, and is solely responsible for the information contained therein.